Phages & antibiotic resistance: Are the most abundant entities on earth ready for a comeback?

Future Microbiology

Volumn 13, Issue 6, 2018, Pages 711-726

  Hill, Colin ^a   Mills, Susan ^a   Ross, Reynolds P ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

antibiotic resistance; bacteriophage; clinical trials; Escherichia coli; phage resistance; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; EASTERN EUROPE; ESCHERICHIA COLI; HISTORY; HISTORY OF MEDICINE; HUMAN; INFECTION; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; WESTERN WORLD; BACTERIAL INFECTION; BACTERIOPHAGE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PROCEDURES;

BACTERIAL INFECTIONS; BACTERIOPHAGES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, BACTERIAL; PHAGE THERAPY;

EID: 85048761741     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2017-0261     Document Type: Review

References (115)

1. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5(1), 226-235 (2014).
2. Spellberg B, Taylor-Blake B. On the exoneration of Dr. William H. Stewart: debunking an urban legend. Infect. Dis. Poverty 2, 3 (2013).
3. World Health Organisation. Antibiotic resistant gonorrhoea on the rise, new drugs needed. (2017). www.who.int/mediacentre/news/releases/2017/Antibiotic-resistant-gonorrhoea/en/
4. Centers for Disease Control and Prevention (CDC). Antibiotic/antimicrobial resistance. (2016). www.cdc.gov/drugresistance/
5. European Medicines Agency (EMA) and European Centre for Disease Prevention and Control (ECDC). The bacterial challenge: time to react a call to narrow the gap between multidrug-resistant bacteria in the EU and development of new antibacterial agents. EMA and ECDC, Stockholm, Sweden (2009). http://ecdc.europa.eu/en/publications/publications/0909 ter the bacterial challenge time to react.pdf
6. Ferrer M, Méndez-García C, Rojo D, Barbas C, Moya A. Antibiotic use and microbiome function. Biochem. Pharmacol. 134, 114-126 (2016).
7. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65(11), 1906-1915 (2016).
8. Theriot CM, Young VB. Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection. Gut Microbes 5(1), 86-95 (2014).
9. Salmond GPC, Fineran PC. A century of the phage: past, present and future. Nat. Rev. Microbiol. 13(12), 777-786 (2015).
10. Hershey AD, Chase M. Independent functions of viral protein and nucleic acid in growth of bacteriophage. J. Gen. Physiol. 36(1), 39-56 (1952).
11. Kutter E, De Vos D, Gvasalia G et al. Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol. 11(1), 69-86 (2010).
12. Kutateladze M. Experience of the Eliava Institute in bacteriophage therapy. Virol. Sin. 30(1), 80-81 (2015).
13. Zschach H, Joensen KG, Lindhard B et al. What can we learn from a metagenomic analaysis of a Georgian bacteriophage cocktail? Viruses 7(12), 6570-6589 (2015).
14. Weber-Dąbrowska B, Jończyk-Matysiak E, Zaczek M et al. Bacteriophage procurement for therapeutic purposes. Front. Microbiol. 7, 1177 (2016).
15. Phage Therapy Unit of the Medical Centre of the Institute of Immunology and Experimental Therapy PAS. www.iitd.pan.wroc.pl/en/OTF/
16. Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr, Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 41, 453-458 (2002).
17. Weber-Dąbrowska B, Mulczyk M, Górski A. Bacteriophages as an efficient therapy for antibiotic-resistant septicaemia in man. Transplant. Proc. 35, 1385-1386 (2003).
18. Jikia D, Chkhaidze N, Imedashvili E et al. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciproflaxicin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin. Exp. Dermatol. 30(1), 23-26 (2005).
19. Leszczyński P, Weber-Dąbrowska B, Kohutnicka M, -Luczak M, Górecki A, Górski A. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker - case report. Folia Microbiol. (Praha) 51(3), 236-238 (2006).
20. Miedzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig. Med. Dosw. 61, 461-465 (2007).
21. Letkiewicz S, Miedzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis case report. Folia Microbiol. (Praha) 54(5), 457-461 (2009).
22. Fadlallah A, Chelala E, Legeais J-M. Corneal infection therapy with topical bacteriophage administration. Open Ophthalmol. J. 9, 167-168 (2015).
23. Schooley RT, Biswas W, Gill JJ et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61(10), pii:e00954-17 (2017).
24. Jennes A, Merabishvili M, Soentjen P et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury - a case report. Crit. Care 21, 129 (2017).
25. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 1(2), 66-85 (2011).
26. Miedzybrodzki R, Borysowski J, Weber-Dąbrowska B et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121 (2012).
27. European Medicines Agency (EMA). Workshop on the therapeutic use of bacteriophages. (2015). www.ema.europa.eu/ema/index.jsp?cu rl=pages/news and events/events/2015/05/event detail 001155.jsp&mid=WC0b01ac058004d5c3
28. European Commission. Directive 2001/83/EC of the European Parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use (consolidated version: 16/11/2012). In: EudraLex - The Rules Governing Medicinal Products in the European Union (Volume 1), Pharmaceutical Legislation: Medicinal Products For Human Use. http://ec.europa.eu/health/files/eudralex/vol-1/dir 2001 83 consol 2012/dir 2001 83 cons 2012 en.pdf
29. Pelfrene E, Willebrand E, Sanches AC, Sebris Z, Cavaleri M. Bacteriophage therapy: a regulatory perspective. J. Antimicrob. Chemother. 71(8), 2071-2074 (2016).
30. Fauconnier A. Regulating phage therapy: the biological master file concept could help to overcome regulatory challenge of personalized medicines. EMBO Rep. 18(2), 198-200 (2017).
31. Kingwell K. Bacteriophage therapies re-enter clinical trials. Nat. Rev. Drug Discov. 14, 515-516 (2015).
32. Parracho HM, Burrowes BH, Enright MC, McConville ML, Harper DR. The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6, 279-286 (2012).
33. Danis-Wlodarczyk K, Vandenheuvel D, Bin Jang H et al. A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections. Sci. Rep. 6, 28115 (2016).
34. Lister PD, Wolter D, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22(4), 582-610 (2009).
35. Hraiech S, Brégeon F, Rolain JM. Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des. Dev. Ther. 9, 3653-3663 (2015).
36. Ceyssens PJ, Noben JP, Ackermann HW et al. Survey of Pseudomonas aeruginosa and its phages: de novo peptide sequencing as a novel tool to assess the diversity of worldwide collected viruses. Environ. Microbiol. 11(5), 1303-1313 (2009).
37. Alemayehu D, Casey PG, McAuliffe O et al. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudmomas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3(2), e00029-12 (2012).
38. Wright A, Hawkins CH, Ángg°ard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34(4), 349-357 (2009).
39. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. J. Wound Care. 18(6), 237-243 (2009).
40. Phagoburn. www.phagoburn.eu
41. Sansom C. Phage therapy for severe infections tested in the first multicentre trial. Lancet 15(12), 1384-1385 (2015).
42. Servick K. Beleaguered phage therapy trial presses on. Science 352(6293), 1506 (2016).
43. Centres for Disease Control and Prevention. Escherichia coli. (2015). www.cdc.gov/ecoli/general/index.html
44. Sarker SA, Brüssow H. From bench to bed and back again: phage therapy of childhood Escherichia coli diarrhoea. Annal. NY Acad. Sci. 1372(1), 42-52 (2016).
45. Tadesse DA, Zhao S, Tong E et al. Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950-2002. Emerg. Infect. Diseases 18(5), 741-749 (2012).
46. Kovacs MJ, Roddy J, Grégoire S, Cameron W, Eidus L, Drouin J. Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli 0157:H7. Am. J. Med. 88(2), 177-179 (1990).
47. Collignon P. Resistant Escherichia coli - we are what we eat. Clin. Infect. Dis. 49(2), 202-204 (2009).
48. Liu YY, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet 16(2), 161-168 (2016).
49. McGann P, Snesrud E, Maybank R et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF Plasmid: first report of mcr-1 in the United States. Antimicrob. Agents Chemother. 60(7), 4420-4421 (2016).
50. Brüssow H. Phage therapy: the Escherichia coli experience. Microbiology 151(7), 2133-2140 (2005).
51. Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49(7), 2874-2878 (2005).
52. Sarker SA, McCallin S, Barretto C et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434(2), 222-232 (2012).
53. McCallin S, Sarker SA, Barretto C et al. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 443(2), 187-196 (2013).
54. Sarker SA, Sultana S, Reuteler G et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBio Med. 4, 124-137 (2016).
55. Jin D, Chen C, Li L et al. Dynamics of fecal microbial communities in children with diarrhea of unknown etiology and genomic analysis of associated Streptococcus lutetiensis. BMC Microbiol. 13, e141 (2013).
56. Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 5(12), 751-762 (2005).
57. Grundmann H, Aanensen DM, van den Wijngaard CC et al. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLOS Med. 7(1) e1000215 (2010).
58. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 13(12), 1840-1846 (2007).
59. Vuong C, Yeh AJ, Cheung GYC, Otto M. Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin. Investig. Drugs 25(1), 73-93 (2016).
60. Centre for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States. (2013). www.cdc.gov/drugresistance/pdf /ar-threats-2013-508.pdf
61. Wang Z, Zheng P, Ji W et al. SLPW: A virulent bacteriophage targeting methicillin sesistant Staphylococcus aureus in vitro and in vivo. Front. Microbiol. 7, 934 (2016).
62. O'Flaherty S, Ross RP, Flynn J, Meaney WJ, Fitzgerald GF, Coffey A. Isolation and characterization of two anti-staphylococcal bacteriophages specific for pathogenic Staphylococcus aureus associated with bovine infections. Lett. Appl. Microbiol. 41(6), 482-486 (2005).
63. Kwiatek M, Parasion S, Mizak L, Gryko R, Bartoszcze M, Kocik J. Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against Staphylococcus aureus strains. Arch. Virol. 157(2), 225-234 (2012).
64. Chang Y, Shin H, Lee JH, Park CJ, Paik SY, Ryu S. Isolation and genome characterization of the virulent Staphylococcus aureus bacteriophage SA97. Viruses 7(10), 5225-5242 (2015).
65. Kaźmierczak Z, Górski A, Dąbrowska K. Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. Viruses 6(7), 2551-2570 (2014).
66. Kutter EM, Kuhl SJ, Abedon ST. Re-establishing a place for phage therapy in western medicine. Future Microbiol. 10(5), 685-688 (2015).
67. Ooi M. A Phase I clinical trial to evaluate the safety, tolerability and preliminary effectiveness of AB-SA01 in patients with chronic rhinosinusitis associated with Staphylococcus aureus infection. Presented at: The 2017 Australian Society of Otolaryngology Head and Neck Surgery Meeting, Adelaide, Australia, 23-26 March 2017.
68. Clokie MRJ, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage 1(1), 31-45 (2012).
69. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut phageome. Proc. Natl Acad. Sci. USA 113(37), 10400-10405 (2016).
70. Breitbart M, Rohwer F. Method for discovering novel DNA viruses in blood using viral particle selection and shotgun sequencing. Biotechniques 39, 729-736 (2005).
71. Fancello L, Monteil S, Popgeorgiev N et al. Viral communities associated with human pericardial fluids in idiopathic pericarditis. PLoS ONE 9(4), e93367 (2014).
72. Weber-Dąbrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. 35, 563-568 (1987).
73. Górski A, Miedzybrodzki R, Borysowski J et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41-74 (2012).
74. Hodyra-Stefaniak K, Miernikiewicz P, Drapa-la J et al. Mammalian host-versus-phage immune response determine phage fate in vivo. Sci. Rep. 5, 14802 (2015).
75. Łusiak-Szelachowska M, Zaczek M, Weber-Dąbrowska B et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27(6), 295-304 (2014).
76. Zaczek M, Łusiak-Szelachowska M, Jończyk-Matysiak E et al. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 7, 1681 (2016).
77. Łusiak-Szelachowska M, Zaczek M, Weber-Dąbrowska B et al. Antiphage activity of sera during phage therapy in relation to its outcome. Future Microbiol. 12(2), 109-117 (2017).
78. Jończyk-Matysiak E, Łusiak-Szelachowska M, K-lak M et al. The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J. Immunol. Res. 2015, 482863 (2015).
79. Singla S, Harjai K, Katare O, Chhibber S. Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS ONE 11(4), e0153777 (2016).
80. Samson JE, Magadán AH, Sabri M, Moineau S. Revenge of the phages: defeating bacterial defences. Nat. Rev. Microbiol. 11(10), 675-687 (2013).
81. Mohanraju P, Makarova KS, Zetsche B, Zhang F, Koonin EV, van der Oost J. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science 353(6299), aad5147 (2016).
82. Chopin MC, Chopin A, Bidnenko E. Phage abortive infection in lactococci: variations on a theme. Curr. Opin. Microbiol. 8(4), 473-479 (2005).
83. Goldfarb T, Sberro H, Weinstock E et al. BREX is a novel phage resistance system widespread in microbial genomes EMBO J. 34(2), 169-183 (2015).
84. Chinenova TA, Mkrtumian NM, Lomovskaia ND. Genetic characteristics of a new phage resistance trait in Streptomyces coelicolor A3(2). Genetika 18(12), 1945-1952 (1982).
85. León M, Bastías R. Virulence reduction in bacteriophage resistant bacteria. Front. Microbiol. 6, 343 (2015).
86. Oechslin F, Piccardi P, Mancini S et al. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J. Infect. Dis. 215, 703-712 (2017).
87. Orndorff PE. Use of bacteriophage to target bacterial surface structures required for virulence: a systematic search for antibiotic alternatives. Curr. Genet. 62(4), 753-757 (2016).
88. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).
89. Nale JY, Spencer J, Hargreaves KR et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob. Agents Chemother. 60(2), 968-981 (2016).
90. Fischer S, Kittler S, Klein G, Glünder G. Impact of a single phage and a phage cocktail application in broilers on reduction of Campylobacter jejuni and development of resistance. PLoS ONE 8(10), e78543 (2013).
91. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother. 54(1) 397-404 (2010).
92. O' Flynn G, Ross RP, Fitzgerald GF, Coffey A. Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl. Environ. Microbiol. 70(6), 3417-3424 (2004).
93. Górski A, Miedzybrodzki R, Weber-Dąbrowska B et al. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front. Microbiol. 7, 1515 (2016).
94. Mattila S, Ruotsalainen P, Jalasvuori M. On-demand isolation of bacteriophages against drug- resistant bacteria for personalized phage therapy. Front. Microbiol. 6, 1271 (2015).
95. O'Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A. Potential of the polyvalent anti-staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl. Environ. Microbiol. 71(4), 1836-1842 (2005).
96. Friman VP, Soanes-Brown D, Sierocinski P et al. Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J. Evol. Biol. 29(1), 188-198 (2016).
97. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE 6(2), e16963 (2011).
98. Mapes AC, Trautner BW, Liao KS, Ramig RF. Development of expanded host range phage active on biofilms of multi-drug resistant Pseudomonas aeruginosa. Bacteriophage 6(1), e1096995 (2016).
99. Ross A, Ward S, Hyman P. More is better: selecting for broad host range bacteriophages. Front. Microbiol. 7, 1352 (2016).
100. Gu J, Liu X, Li Y et al. A method for generation phage cocktail with great therapeutic potential. PLoS ONE 7(3), e31698 (2012).
101. Raya RR, Oot RA, Moore-Maley B et al. Naturally resident and exogenously applied T4-like and T5-like bacteriophages can reduce Escherichia coli O157:H7 levels in sheep guts. Bacteriophage 1, 15-24 (2011).
102. Gill JJ, Hyman P. Phage choice isolation and preparation for phage therapy. Curr. Pharm. Biotechnol. 11(1), 2-14 (2010).
103. Tawil N, Sacher E, Mandeville R, Meunier M. Bacteriophages: biosensing tools for multi-drug resistant pathogens. Analyst 139(6), 1224-1236 (2014).
104. Denyes JM, Dunne M, Steiner S et al. Modified bacteriophage S16 long tail fiber proteins for rapid and specific immobilization and detection of Salmonella cells. Appl. Environ. Microbiol. 83(12), e00277-17 (2017).
105. Bárdy P, Pant°uček R, Benšík M, Doškař J. Genetically modified bacteriophages in applied microbiology. J. Appl. Microbiol. 121(3), 618-633 (2016).
106. Expert Round Table on Acceptance and Re-Implementation of Bacteriophage Therapy. Silk route to the acceptance and reimplementation of bacteriophage therapy. Biotechnol. J. 11(5), 595-600 (2016).
107. Kirby AE. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS ONE 7(1), e51017 (2012).
108. Davies JK. Genomics and recombination. In: Neisseria, Molecular Mechanisms of Pathogenesis. Genco CA, Wetzler L (Eds). Caister Academic Press, Norfolk, UK, 41-51 (2010).
109. Piekarowicz A, K-lyz A, Majchrzak M, Stein DC. Oral immunization of rabbits with S. enterica Typhimurium expressing Neisseria gonnorrhoeae filamentous phage F6 induces bacterial antibodies against N. gonnorrhoeae. Sci. Rep. 6, 22549 (2016).
110. O'Flaherty S, Coffey A, Meaney WJ, Fitzgerald GF, Ross RP. Inhibition of bacteriophage K proliferation on Staphylococcus aureus in raw bovine milk. Lett. Appl. Microbiol. 41(3), 274-279 (2005).
111. Górski A, Dąbrowska K, Miedzybrodzki R et al. Phages and immunomodulation. Future Microbiol. 12(10), 905-914 (2017).
112. Górski A, Jonczyk-Matysiak E, Łusiak-Szelachowska M, Miedzybrodzki R, Weber-Dąbrowska B, Borysowski J. Bacteriophages targeting intestinal epithelial cells: a potential novel form of immunotherapy. Cell. Mol. Life Sci. 75(4), 589-595 (2017).
113. Reyes A, Semenkovich NP, Whiteson K, Rohwer F, Gordon JI. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat. Rev. Microbiol. 10, 607-617 (2012).
114. Miedzybrodzki R, Borysowski J, KI-lak M et al. In vivo studies on the influence of bacteriophage preparations on the autoimmune inflammatory process. Biomed. Res. Int. 2017, 3612015 (2017).
115. Akimkin VG, Kalmykov AA, Aminev RM, Polyakov VS, Artebyakin SV. Experience of using bacteriophage and bitilisin-5 to reduce the incidence of respiratory diseases of bacterial ethiology in military personnel. Voen. Med. Zh. 337(2), 36-40 (2016).